FDA Approves Dosage of Pancreatic Enzyme Supplement ZENPEP® for Infants
June 17, 2011
Aptalis Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a new dosage of its pancreatic enzyme replacement therapy ZENPEP® (pancrelipase) formulated specifically for infants.
Earlier this week the FDA approved an infant-specific dosage of the pancreatic enzyme CREON®, made by Abbott Laboratories.
The lower-strength capsules allow for a more precise and consistent dose of pancreatic enzyme supplements to be given to infants with cystic fibrosis.
Read more in the full release from Aptalis.